Evidence map›Paper›PMID 39296159›Full record

ArticleHeliyon2024

Maha B Salem, Mohamed Elzallat, Dina Mostafa Mohammed, Olfat A Hammam, Marwa Tamim A Abdel-Wareth, Marwa Hassan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Toxicology reports · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maha B SalemPharmacology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Mohamed ElzallatImmunology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Dina Mostafa MohammedNutrition and Food Sciences Department, National Research Centre, Dokki, Giza, 12622, Egypt.
Olfat A HammamPathology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Marwa Tamim A Abdel-WarethEnvironmental Research Department, Theodor Bilharz Research Institute, Giza, Egypt.
Marwa HassanImmunology Department, Theodor Bilharz Research Institute, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut microbiota imbalance and alterations in the chemokine-chemokine receptor interactions are pivotal in the initiation and advancement of ulcerative colitis (UC). The current UC treatments are prolonged, exhibit high recurrence rates, and may lead to colorectal cancer. So, this study explores the efficacy of

Indexed as

BacteriodetesChemokineFirmicutesHelix pomatia mucinOxidative stressUlcerative colitis

Identifiers

PMID39296159
PMCPMC11407997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.